TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31604781

Group type: EXPERIMENTAL
Intervention: Lifestyle factors assessment including dietary pattern, physical activity, cardiovascular fitness, and sleep.
Number of subjects: 840

Group type: EXPERIMENTAL
Intervention: Medical history, socioeconomic status, alcohol and tobacco consumption, cognition, stress, anxiety, and early life experiences documentation.
Number of subjects: 840

Group type: EXPERIMENTAL
Intervention: Body composition and bone density measurement by dual energy X-ray absorptiometry.
Number of subjects: 840

Group type: EXPERIMENTAL
Intervention: Blood pressure, pulse wave velocity, and augmentation index measurement on two consecutive days.
Number of subjects: 840

Group type: EXPERIMENTAL
Intervention: Chronic disease risk biomarkers measured in blood and urine samples.
Number of subjects: 840

Group type: EXPERIMENTAL
Intervention: DNA extraction for genetic analysis.
Number of subjects: 840

Group type: EXPERIMENTAL
Intervention: Faecal sample collection for microbiome analysis.
Number of subjects: 840
Study: 31604785

Group type: EXPERIMENTAL
Intervention: Transhepatic flow changes following major liver resection
Number of subjects: 50
Study: 31604788

Group type: EXPERIMENTAL
Intervention: Cluster 1 (22% refusal rate)
Number of subjects: 642

Group type: EXPERIMENTAL
Intervention: Cluster 2 (38% refusal rate)
Number of subjects: 642

Group type: EXPERIMENTAL
Intervention: Cluster 3 (62% refusal rate)
Number of subjects: 642
Study: 31605106

Group type: EXPERIMENTAL
Intervention: larotrectinib 100 mg twice daily
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: selitrectinib 100 mg twice daily
Number of subjects: 1

Group type: COMPARATOR
Intervention: gemcitabine, nab-paclitaxel and ADI-PEG 20
Number of subjects: 1

Group type: COMPARATOR
Intervention: modified regimen of folinic acid, fluorouracil, irinotecan and oxaliplatin
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: dabrafenib-trametinib combination therapy
Number of subjects: 1
Study: 31605278

Group type: EXPERIMENTAL
Intervention: Standard split dose of 4 l polyethylene glycol for bowel preparation
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: Bristol stool form scale (BSFS) 1
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: Rectal pain score during defecation < 2
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: Starting-to-defecation interval ≥ 4 h
Number of subjects: 199

Group type: COMPARATOR
Intervention: No risk factors
Number of subjects: 199

Group type: COMPARATOR
Intervention: 1 risk factor
Number of subjects: 199

Group type: COMPARATOR
Intervention: 2 risk factors
Number of subjects: 199

Group type: COMPARATOR
Intervention: 3 risk factors
Number of subjects: 199
Study: 31605514

Group type: EXPERIMENTAL
Intervention: 12-week physical activity intervention
Number of subjects: 87

Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 87
Study: 31605516

Group type: EXPERIMENTAL
Intervention: Automated mental health resources via smartphone technology (Pocket Helper 2.0 app)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Daily tips and daily surveys from the Pocket Helper 2.0 app
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Automated self-help system and app providing up-to-date resources
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Interactive features (telephone hotline and crowd-based emotional support tool)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Participant retention
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Problems with phones (theft, loss, technological issues)
Number of subjects: 100
Study: 31605903

Group type: EXPERIMENTAL
Intervention: AHI > 15
Number of subjects: 302

Group type: COMPARATOR
Intervention: AHI < 15
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: AHI
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: Nocturnal hypoxemia (T90%)
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: 3% oxygen desaturation index (ODI3)
Number of subjects: 302
Study: 31606044

Group type: EXPERIMENTAL
Intervention: S5 methylation classifier
Number of subjects: 316

Group type: COMPARATOR
Intervention: HPV16/18 detection
Number of subjects: 316

Group type: COMPARATOR
Intervention: Cytology
Number of subjects: 316
Study: 31606309

Group type: EXPERIMENTAL
Intervention: MELD-XI score > 12
Number of subjects: 11091

Group type: EXPERIMENTAL
Intervention: MELD-XI score
Number of subjects: 11091
Study: 31606419

Group type: EXPERIMENTAL
Intervention: Tisagenlecleucel infusion
Number of subjects: 75
Study: 31606880

Group type: EXPERIMENTAL
Intervention: Ipragliflozin 50 mg
Number of subjects: 2005

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2005
Study: 31606970

Group type: EXPERIMENTAL
Intervention: Autologous cultured fibroblasts, 3 injections administered at 4-6 week intervals.
Number of subjects: 57
Study: 31606971

Group type: EXPERIMENTAL
Intervention: Gene sequencing and DNA-based fragment polymorphism analysis
Number of subjects: 95

Group type: COMPARATOR
Intervention: Conventional morphology
Number of subjects: 95

Group type: COMPARATOR
Intervention: PCR-RFLP
Number of subjects: 95
Study: 31607151

Group type: EXPERIMENTAL
Intervention: Self-expanding TAVR
Number of subjects: 226
Study: 31607204

Group type: EXPERIMENTAL
Intervention: Long-acting liquid methylphenidate
Number of subjects: 0
Study: 31607268

Group type: EXPERIMENTAL
Intervention: Infliximab (IFX) 5 mg/kg at Weeks 0, 2, and 6, with additional doses at Weeks 14 and 22 for CAI-based responders
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Infliximab (IFX)
Number of subjects: 21
Study: 31607443

Group type: EXPERIMENTAL
Intervention: Crizotinib
Number of subjects: 48
Study: 31608213

Group type: EXPERIMENTAL
Intervention: 12-week Interferon-based Danoprevir Regimen
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 31608217

Group type: EXPERIMENTAL
Intervention: Peg-interferon Alpha-2a
Number of subjects: 0
Study: 31608488

Group type: EXPERIMENTAL
Intervention: ACLR limb
Number of subjects: 73

Group type: COMPARATOR
Intervention: Contralateral limb
Number of subjects: 73
Study: 31609525

Group type: EXPERIMENTAL
Intervention: Female sex
Number of subjects: 458

Group type: COMPARATOR
Intervention: Male sex
Number of subjects: 458
Study: 31609651

Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 74
Study: 31609771

Group type: EXPERIMENTAL
Intervention: Preoperative diaphragm thickening fraction (TFdi,max)
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: TFdi,max < 38.1%
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: TFdi,max (37% [IQR, 31-45%] vs 44% [IQR, 33-58%])
Number of subjects: 115
Study: 31611106

Group type: EXPERIMENTAL
Intervention: Self-expandable stent grafts (SESGs)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Balloon-expandable stent grafts (BESGs)
Number of subjects: 126
Study: 31611259

Group type: EXPERIMENTAL
Intervention: MR1-independent activation of human mucosal-associated invariant T cells by Mycobacteria
Number of subjects: 0
Study: 31611263

Group type: COMPARATOR
Intervention: Psychotic symptoms in patients with Huntington disease
Number of subjects: 1082
Study: 31611617

Group type: EXPERIMENTAL
Intervention: Passing challenge testing
Number of subjects: 80

Group type: COMPARATOR
Intervention: Failing challenge testing with periodic breathing
Number of subjects: 80
Study: 31611759

Group type: EXPERIMENTAL
Intervention: S-ketamine
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 31611917

Group type: EXPERIMENTAL
Intervention: Compuflo® Epidural instrument
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional Training
Number of subjects: 0
Study: 31611935

Group type: EXPERIMENTAL
Intervention: Butorphanol
Number of subjects: 131

Group type: COMPARATOR
Intervention: 0.9% Saline
Number of subjects: 131
Study: 31612072

Group type: EXPERIMENTAL
Intervention: Patients with ESUS
Number of subjects: 101

Group type: COMPARATOR
Intervention: Controls
Number of subjects: 101
Study: 31612225

Group type: EXPERIMENTAL
Intervention: Combination antiretroviral therapy (cART) initiated irrespective of CD4 cell count, with a median delay in initiation decreasing from 9.07 months in 2007 to 0.77 months in 2017.
Number of subjects: 61822

Group type: EXPERIMENTAL
Intervention: Achieving the second and third Joint United Nations Programme on HIV/AIDS 90-90-90 targets.
Number of subjects: 61822
Study: 31612640

Group type: EXPERIMENTAL
Intervention: PEG-asparaginase in Total XVI (TXVI)
Number of subjects: 1096

Group type: COMPARATOR
Intervention: native Escherichia coli l-asparaginase in Total XV (TXV)
Number of subjects: 1096

Group type: EXPERIMENTAL
Intervention: asparaginase
Number of subjects: 1096

Group type: EXPERIMENTAL
Intervention: drug effects
Number of subjects: 1096
Study: 31613140

Group type: EXPERIMENTAL
Intervention: FreeStyle Libre
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 31613224

Group type: EXPERIMENTAL
Intervention: Hypothermic oxygenated machine perfusion (HOPE) for 2 hours via renal artery before implantation.
Number of subjects: 45

Group type: COMPARATOR
Intervention: Conventional cold storage (control group).
Number of subjects: 45
Study: 31613310

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 31613328

Group type: EXPERIMENTAL
Intervention: Investigational norovirus vaccine
Number of subjects: 24
Study: 31613706

Group type: EXPERIMENTAL
Intervention: Oatmeal consumption (2 servings of instant oatmeal daily for 2 weeks)
Number of subjects: 33
Study: 31615411

Group type: EXPERIMENTAL
Intervention: dsDNA levels measured in serum
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: PAD4 mRNA measured in circulating leukocytes
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: MPO-DNA levels measured in serum
Number of subjects: 224
Study: 31615432

Group type: EXPERIMENTAL
Intervention: Serum phosphate levels
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Intact parathyroid hormone (iPTH) levels
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: C-terminal fibroblast growth factor 23 (cFGF23) levels
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Serum cFGF23 levels
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Bone-specific alkaline phosphatase (BAP) levels
Number of subjects: 158
Study: 31615452

Group type: EXPERIMENTAL
Intervention: Neutrophil gelatinase-associated lipocalin (NGAL) measured at 6 hours after surgery
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Plasma NGAL (PNGAL) measured at 18 hours after LT
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Neutrophil gelatinase-associated lipocalin (NGAL) measured at 6 hours and 18 hours after LT
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Neutrophil gelatinase-associated lipocalin (NGAL) measured at 18 hours after LT
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Neutrophil gelatinase-associated lipocalin (NGAL) measured at 6 hours after LT
Number of subjects: 100
Study: 31615553

Group type: EXPERIMENTAL
Intervention: Tranexamic acid (given intravenously or orally)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31615556

Group type: EXPERIMENTAL
Intervention: Floseal® treatment
Number of subjects: 7
Study: 31615560

Group type: EXPERIMENTAL
Intervention: DuraGraft
Number of subjects: 3000
Study: 31615852

Group type: EXPERIMENTAL
Intervention: Islet transplantation alone (ITA)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Islet transplantation after kidney graft (IAK)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Islet transplantation (both ITA and IAK)
Number of subjects: 28
Study: 31616147

Group type: EXPERIMENTAL
Intervention: Patient-reported cognitive symptoms (5-item Perceived Deficits Questionnaire score)
Number of subjects: 1159

Group type: EXPERIMENTAL
Intervention: Functional impairment (Sheehan Disability Scale total score)
Number of subjects: 1159

Group type: EXPERIMENTAL
Intervention: Depression severity (9-item Patient Health Questionnaire score)
Number of subjects: 1159
Study: 31616148

Group type: EXPERIMENTAL
Intervention: Aripiprazole once monthly (AOM 400)
Number of subjects: 229

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 229
Study: 31616309

Group type: EXPERIMENTAL
Intervention: Autologous mesenchymal stem cells (MSCs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Allogeneic mesenchymal stem cells (MSCs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MSC secretion of SDF-1α
Number of subjects: 0
Study: 31616348

Group type: EXPERIMENTAL
Intervention: Mindfulness-based instructions and EEG neurofeedback
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Bispectral Index neurofeedback
Number of subjects: 57
Study: 31616411

Group type: EXPERIMENTAL
Intervention: Circulating innate lymphoid cell subpopulations
Number of subjects: 0
Study: 31617114

Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGB)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Non-operated controls (CON)
Number of subjects: 84
Study: 31617211

Group type: EXPERIMENTAL
Intervention: Thrombocytosis (platelet count > 500 × 10^9/L)
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: High platelet counts leading to bleeding complications
Number of subjects: 156
Study: 31617269

Group type: EXPERIMENTAL
Intervention: Tabalumab (NTC00882999) - a BAFF inhibitor
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Atacicept (NCT00642902) - an APRIL and BAFF inhibitor
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BAFF inhibition
Number of subjects: 0
Study: 31617432

Group type: EXPERIMENTAL
Intervention: Alisertib (MLN8237) combined with vorinostat
Number of subjects: 0
Study: 31617910

Group type: EXPERIMENTAL
Intervention: Overweight or obesity
Number of subjects: 4013

Group type: COMPARATOR
Intervention: Normal weight (control group)
Number of subjects: 4013
Study: 31618131

Group type: EXPERIMENTAL
Intervention: Exemestane plus ovarian function suppression (OFS)
Number of subjects: 4891

Group type: EXPERIMENTAL
Intervention: Exemestane plus OFS
Number of subjects: 4891

Group type: COMPARATOR
Intervention: Tamoxifen plus OFS
Number of subjects: 4891

Group type: COMPARATOR
Intervention: Tamoxifen alone
Number of subjects: 4891
Study: 31618297

Group type: EXPERIMENTAL
Intervention: High-intensity pulmonary rehabilitation program (PRP)
Number of subjects: 25
Study: 31618421

Group type: EXPERIMENTAL
Intervention: Hourly mixed meals providing variable protein (0.20-3.00 g·kg-1·d-1) as crystalline amino acids modeled after egg protein
Number of subjects: 7
Study: 31618746

Group type: EXPERIMENTAL
Intervention: Serial urinary [TIMP-2] × [IGFBP7] measured at baseline, 12 and 24 hours, and up to 3 days
Number of subjects: 530

Group type: EXPERIMENTAL
Intervention: Three consecutive negative values (≤0.3 (ng/mL)2/1,000)
Number of subjects: 530

Group type: EXPERIMENTAL
Intervention: Emerging or persistent strongly positive results (>2.0 (ng/mL)2/1,000)
Number of subjects: 530

Group type: EXPERIMENTAL
Intervention: Test results between 0.3 and 2.0 (ng/mL)2/1,000
Number of subjects: 530
Study: 31618760

Group type: EXPERIMENTAL
Intervention: Automated topographic (T) method
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Metric (M) method
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Automated topographic (T) method without 10-2
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Metric (M) method without 10-2
Number of subjects: 53

Group type: COMPARATOR
Intervention: Automated topographic (T) method in healthy controls
Number of subjects: 53
Study: 31618804

Group type: EXPERIMENTAL
Intervention: Subcutaneous N8-GP (12.5, 25, 50, or 100 IU/kg single dose in part A; 2000 IU for patients <60 kg and 4000 IU for patients ≥60 kg daily for 3 months in part B)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Subcutaneous N8-GP
Number of subjects: 50
Study: 31618841

Group type: EXPERIMENTAL
Intervention: High probability of pulmonary hypertension (PH) based on echocardiographic evaluation according to ESC guidelines
Number of subjects: 657

Group type: COMPARATOR
Intervention: Low probability of pulmonary hypertension (PH) based on echocardiographic evaluation according to ESC guidelines
Number of subjects: 657
Study: 31619150

Group type: EXPERIMENTAL
Intervention: Higher contralateral cerebral blood flow (cCBF)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Lower contralateral cerebral blood flow (cCBF)
Number of subjects: 77
Study: 31619287

Group type: EXPERIMENTAL
Intervention: Obesity defined by BMI (26.9% prevalence)
Number of subjects: 791

Group type: EXPERIMENTAL
Intervention: Increased waist circumference
Number of subjects: 791

Group type: EXPERIMENTAL
Intervention: Disease activity evaluated using DAS28
Number of subjects: 791
Study: 31619290

Group type: EXPERIMENTAL
Intervention: Rituximab-maintenance therapy (375 mg/m2), 2 years duration after R-CVP treatment
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Rituximab-maintenance therapy
Number of subjects: 47
Study: 31619433

Group type: COMPARATOR
Intervention: Prefrail individuals (1-2 frailty components)
Number of subjects: 7327

Group type: COMPARATOR
Intervention: Frail individuals (≥3 frailty components)
Number of subjects: 7327

Group type: EXPERIMENTAL
Intervention: Non-frail individuals (0 frailty components)
Number of subjects: 7327

Group type: EXPERIMENTAL
Intervention: Overall associations with frailty status
Number of subjects: 7327
Study: 31619435

Group type: EXPERIMENTAL
Intervention: Acute surgical approach (surgery directly after the first CT at presentation)
Number of subjects: 1750

Group type: EXPERIMENTAL
Intervention: Craniotomy
Number of subjects: 1750

Group type: COMPARATOR
Intervention: Expectant approach (late or no surgery)
Number of subjects: 1750

Group type: COMPARATOR
Intervention: Decompressive craniectomy
Number of subjects: 1750

Group type: EXPERIMENTAL
Intervention: In-hospital mortality
Number of subjects: 1750

Group type: EXPERIMENTAL
Intervention: Quality of life
Number of subjects: 1750

Group type: EXPERIMENTAL
Intervention: Neuropsychological tests
Number of subjects: 1750
Study: 31619468

Group type: EXPERIMENTAL
Intervention: NTM-PD patients
Number of subjects: 1445
Study: 31619706

Group type: EXPERIMENTAL
Intervention: Carfilzomib-lenalidomide-dexamethasone (KRd) therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cereblon gene variants (CRBN rs1672753)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cereblon gene variants (CRBN rs1714327)
Number of subjects: 0
Study: 31620067

Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (standard care)
Number of subjects: 0
Study: 31620073

Group type: EXPERIMENTAL
Intervention: Aerobic training, details on dosage and duration not specified
Number of subjects: 0
Study: 31620671

Group type: EXPERIMENTAL
Intervention: Groundwater iron presence
Number of subjects: 2878

Group type: EXPERIMENTAL
Intervention: Groundwater iron presence with no vitamin C-rich or heme-iron foods consumed
Number of subjects: 2878

Group type: EXPERIMENTAL
Intervention: Groundwater iron presence with intake of vitamin C-rich foods
Number of subjects: 2878

Group type: EXPERIMENTAL
Intervention: Heme-iron and vitamin C consumption
Number of subjects: 2878

Group type: EXPERIMENTAL
Intervention: Groundwater iron presence with heme-iron or vitamin C-rich foods
Number of subjects: 2878
Study: 31620672

Group type: EXPERIMENTAL
Intervention: Legume supplement providing 8.2 g/d of protein
Number of subjects: 0
Study: 31620787

Group type: EXPERIMENTAL
Intervention: Disease activity (DA) evaluated according to SELENA-SLEDAI flare index (SFI) and revised SELENA-SLEDAI flare index (SFI-R)
Number of subjects: 336

Group type: COMPARATOR
Intervention: Remitting patients
Number of subjects: 336
Study: 31620836

Group type: EXPERIMENTAL
Intervention: Appropriate antibiotic treatment
Number of subjects: 2960

Group type: COMPARATOR
Intervention: Inappropriate antibiotic treatment
Number of subjects: 2960
Study: 31620921

Group type: EXPERIMENTAL
Intervention: MIRUS™ with isoflurane, sevoflurane, or desflurane at 0.5 MAC
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 30
Study: 31621458

Group type: EXPERIMENTAL
Intervention: Immune globulin subcutaneous, human - klhw 20%
Number of subjects: 0
Study: 31621477

Group type: EXPERIMENTAL
Intervention: SUPERA™ stent and drug-coated balloon (Passeo-18 Lux™)
Number of subjects: 20
Study: 31622688

Group type: EXPERIMENTAL
Intervention: Severe asthma intervention (not specified)
Number of subjects: 111
Study: 31623522

Group type: EXPERIMENTAL
Intervention: Fasting and postprandial triglyceride-rich lipoprotein particle (TRLP) concentrations and size in black women
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Very small TRLP concentrations
Number of subjects: 122
Study: 31623657

Group type: EXPERIMENTAL
Intervention: Predictive model for men based on independent factors such as age, tobacco use, severe and permanent pain, retrosternal pain, breathing non-related pain, radiating pain, and additional symptoms.
Number of subjects: 3727

Group type: EXPERIMENTAL
Intervention: Predictive model for women based on independent factors such as age ≥ 60 years, personal history of coronary artery disease, breathing non-related pain, and radiating pain.
Number of subjects: 3727
Study: 31623840

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (DEX)
Number of subjects: 122
Study: 31623843

Group type: EXPERIMENTAL
Intervention: Ultra-processed food consumption (average 385 g/d, 24.4% of total energy intake)
Number of subjects: 11898

Group type: COMPARATOR
Intervention: Isocaloric substitution of ultra-processed food with unprocessed or minimally processed foods
Number of subjects: 11898
Study: 31624865

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 31624942

Group type: EXPERIMENTAL
Intervention: Third space robotic and endoscopic cooperative surgery (TS-RECS)
Number of subjects: 20
Study: 31626037

Group type: EXPERIMENTAL
Intervention: Various treatment strategies (19 different strategies applied)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Ferritin measurement at diagnosis
Number of subjects: 40
Study: 31626649

Group type: EXPERIMENTAL
Intervention: Liquorice ingestion (290-370 mg/d glycyrrhizin)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Sublingual nitroglycerin (0.25 mg)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Inhaled salbutamol (400 μg)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Liquorice ingestion
Number of subjects: 42

Group type: COMPARATOR
Intervention: Reference group (control)
Number of subjects: 42
Study: 31627014

Group type: EXPERIMENTAL
Intervention: Semantic naming treatment for 12 weeks
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Patients with chronic aphasia pre-treatment
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Patients with chronic aphasia post-treatment
Number of subjects: 26
Study: 31627210

Group type: EXPERIMENTAL
Intervention: Patients with pain (PBI > 2, N = 28)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Patients with no pain (PBI score ≦ 2, N = 11)
Number of subjects: 39